<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556188</url>
  </required_header>
  <id_info>
    <org_study_id>AISCaSS</org_study_id>
    <nct_id>NCT04556188</nct_id>
  </id_info>
  <brief_title>The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa</brief_title>
  <acronym>RHD-CaSS</acronym>
  <official_title>The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Nord-Trøndelag HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Nord-Trøndelag HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this bi-directional program of education, training and research activities based on&#xD;
      sustainable development goals aim is to develop cardiac surgery service in Ethiopia.&#xD;
&#xD;
      The aim is to evaluate the short and long-term outcome of cardiac surgery for rheumatic heart&#xD;
      disease in a low-income country compared to individuals not offered cardiac surgery due to&#xD;
      limited availability of the service. Second aim is to evaluate the quality of anticoagulant&#xD;
      therapy in patients after cardiac surgery for rheumatic heart disease in a low-income country&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our objectives are:&#xD;
&#xD;
        1. To evaluate the 30- and 180-days outcome of cardiac surgery for rheumatic heart disease&#xD;
           (RHD), and impact of gender, age, clinical findings and echocardiographic&#xD;
           classification, during the time of development of cardiac surgery at Black Lion&#xD;
           hospital, Ethiopia, in comparison with matched individuals (from the same waiting list)&#xD;
           which had no offer of surgery due to limited availability.&#xD;
&#xD;
        2. To evaluate the quality of anticoagulation therapy after cardiac surgery at Black Lion&#xD;
           hospital, Ethiopia by evaluating the patients proportion of time in therapeutic&#xD;
           INR-level, complications as valve dysfunction, bleeding and thrombosis compared to&#xD;
           control patients undergoing valvular replacement due to RHD at Norwegian hospitals.&#xD;
&#xD;
      Population: Approximately 50 RHD patients operated by Our team at Addis Abeba University&#xD;
      Hospital, Ethiopia.&#xD;
&#xD;
      Follow up for 180-days for objective 1 and continous follow-up for objective 2. Comparison&#xD;
      With matched Controls. Outcome measures: Mortality, complications (heart failure,&#xD;
      arrhythmias, thrombosis, bleedings, stroke, infections)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Short term outcome</measure>
    <time_frame>180 days</time_frame>
    <description>Freedom from Death or complication</description>
  </primary_outcome>
  <other_outcome>
    <measure>Time in therapeutic INR</measure>
    <time_frame>2 years</time_frame>
    <description>Time in therapeutic window (anticoagulation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve area by Doppler</measure>
    <time_frame>14 days</time_frame>
    <description>Influence of concomitant pathology for Echocardiographic assessment of mitral stenosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral phenotype in rheumatic heart disease</measure>
    <time_frame>0 days</time_frame>
    <description>Influence of mitral valve phenotype with cardiac morphology and complications in untreated rheumatic heart disease patients</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatic Heart Disease</condition>
  <condition>Anticoagulant Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RHD controls</arm_group_label>
    <description>RHD patients not offered Cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation controls</arm_group_label>
    <description>Norwegian patients on anticoagulant therapy due to mechanical valve implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac surgery</intervention_name>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cases: Patients offered Cardiac surgery due to indication symptomatic rheumatic heart&#xD;
        disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cardiac surgery due to rheumatic heart disease at the governmental Black Lion&#xD;
             University Hospital during the bi-directional programme of education, training and&#xD;
             Research to establish Cardiac surgery service&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing or able to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Black Lion University Hospital</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7491</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Heart Disease</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No written plan. Under discussion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

